Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report

The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: A. A. Semenova, P. A. Zeynalova, M. S. Nikitina, M. I. Akhmedov
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: ABV-press 2019-01-01
Sarja:Onkogematologiâ
Aiheet:
brentuximab vedotin (adcetris®)
relapse of anaplastic large cell lymphoma
eosinophilia
tumor lysis syndrome
Linkit:https://oncohematology.abvpress.ru/ongm/article/view/320
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia